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Objectives: Bacterial resistance patterns vary over time
and geography. Surveillance studies help to identify those
patterns to help guide therapy. The Tigecycline Evaluation
Surveillance Trial (TEST) is an ongoing global surveillance
study that serves to recognize current trends in resis-
tance. This report evaluates differences in susceptibilities
of strains from different body sites, collected in Europe
2004—2007.
Methods: 21,381 strains isolated from 8 body sites were
collected and identiﬁed from 2004—2007 at 79 hospitals in
22 countries in Europe. MICs for each strain were deter-
mined per EUCAST guidelines at each facility using broth
microdilution. MIC50/90 was analyzed to identify any signiﬁ-
cant differences in antibiograms from different sources.
Results: Tigecycline (TIG) MIC50 values for almost all
organism/specimen pairings were ±2 log2 dilutions of each
other, with no single source giving a higher MIC50 than the
others. The same was seen for TIG MIC90 values, which were
also almost always within 1—2 log2 dilutions of the MIC50,
except for S. pneumoniae, whose TIG MIC90 were 3—4 fold
higher than the MIC50 for all specimen sources. Comparator
drugs also generally showed no variability in susceptibility
of isolates from various body sites. A notable exception was
E. faecium vs. vancomycin, for which the MIC90 of blood
isolates was signiﬁcantly higher than other sources.
Conclusions: Bacteria isolated from more than 8 differ-
ent body sites had generally similar antibiograms, with no
isolates from any single source showing signiﬁcantly differ-
ent sensitivity patterns. TIG’s broad spectrum of activity
and consistently low MIC90/MIC50 ratios, including strains
resistant to other drugs, may make it an excellent therapeu-
tic option when treating infections often caused by strains
refractory to treatment with other agents.
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Background: The Tigecycline In-Vitro Surveillance in Tai-
wan (TIST), initiated in 2006, is a nationwide surveillance
program designed to monitor longitudinally the in vitro
activities of tigecycline against commonly encountered
resistant bacteria in Taiwan. This study aims to determine
the in vitro activities of tigecycline against clinical iso-
lates of Extended-Spectrum--lactamase-(ESBL)-producing
Enterobacteriaceae in Taiwan.
Methods: A total of 620 isolates of ESBL-producing iso-
lates, including Escherichia coli, Klebsiella pneumoniae, K.
oxytoca, and Proteus mirabilis were collected from vari-
ous sources of patients treated at 20 teaching hospitals.
Minimum inhibitory concentrations (MICs) for tigecycline
and ESBL phenotype of these isolates were determined by
the broth microdilution methods according the guidelines
described by Clinical and Laboratory Standards Institute
(CLSI) and interpreted by the MIC criteria provided by U.S.
FDA.
Results: The results are shown in the table 1.
Conclusion: Tigecycline exhibited excellent in vitro
activities against ESBL-producing Enterobacteriaceae (sus-
ceptible >98%) in Taiwan, except for P. mirabilis (73%)
isolates.
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